Rasagiline in the Treatment of Persistent Negative Symptoms of Schizophrenia

The study will consist of two phases: a 4-week continued stability phase (lead-in phase) and
a 12-week double-blind treatment phase. In the lead-in phase, subjects receiving
antipsychotic medication, who manifest moderate to severe and persistent negative symptoms,
will remain on their maintenance regimen for at least four weeks. The treatment phase will be
a 12-week, parallel groups, double-blind, placebo-controlled trial of adjunctive rasagiline
(1 mg/day), a selective MAO-B oxidase inhibitor.

Inclusion Criteria:

- Subjects will meet DSM-IV criteria for schizophrenia or schizoaffective disorder.

- Current treatment with one or more second generation antipsychotics, except
ziprasidone

- On same second generation antipsychotic(s)for at least 56 days

- On same dose of second generation antipsychotic(s)for at least 30 days

- 22-item SANS: Total score (i.e.all items minus global items and poverty of content of
speech)greater than 20 or global Rating of Affective Flattening greater than or equal
to 3 or global Rating of alogia greater than or equal to 3

- BPRS: Sum of the four positive symptom items less than or equal to 16 (items
4,11,12,15)

- BPRS: Sum of the four Anxiety/Depression Factor items less than or equal to 14 (items
1,2,5,9)

- Simpson-Angus Scale: Total score less than or equal to 8

Exclusion Criteria:

- DSM-IV Major Depressive Disorder within last 6 months

- Current treatment with ziprasidone

- DSM-IV diagnosis of alcohol or substance dependence within the last 6 months

- DSM-IV criteria for alcohol or substance abuse within the last month

- evidence of illicit substance use, as identified with urine toxicology screen

- History of an organic brain disorder, mental retardation,epilepsy, or a medical
condition, whose pathology or treatment could alter the presentation or treatment of
schizophrenia or significantly increase the risk associated with the proposed
treatment protocol. See those listed below

- Uncontrolled hypertension defined as BP exceeding 145/90 on 3 consecutive readings
despite adequate treatment, pheochromocytoma, melanoma, hepatic insufficiency

- Pregnancy or lactation in females

- Pheochromocytoma

- Melanoma

- Hepatic insufficiency